Myasthenia Gravis

HORSHAM, Pa., April 22, 2026 Johnson & Johnson has reported compelling long-term Phase 3 data demonstrating that IMAAVY® (nipocalimab-aahu)...

Cambridge, UK, 30 October 2025 – Alexion, AstraZeneca Rare Disease, today announced positive results from the global Phase III...

Emeryville, California, October 29, 2025 — Kyverna Therapeutics Inc. (Nasdaq: KYTX) announced positive interim Phase 2 data from the...